- Joined
- Feb 21, 2002
- Messages
- 4,358
- Reaction score
- 4,703
FDA finalizes guidance to spur biosimilar availability
The guidance will help companies develop biosimilars that can be interchanged at the pharmacy without the need to contact a doctor.
www.modernhealthcare.com
Statement from Acting FDA Commissioner Ned Sharpless, M.D., on policy advancements to help bring interchangeable biosimilars to market
FDA announces final guidance on the pathway for “interchangeable” biologics, which may be substituted without the involvement of the prescriber.
www.fda.gov
That's going to be very interesting for BIO. I wouldn't suggest dumping your Amgen or Genentech yet, but the biologics market is going to be interesting in about five to seven years from now.